Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin

被引:3
作者
Fujii, Miharu [1 ]
Yasuda, Kaori [1 ]
Sakaki, Toshiyuki [1 ]
机构
[1] Toyama Prefectural Univ, Fac Engn, Dept Pharmaceut Engn, 5180 Kurokawa, Imizu, Toyama 9390398, Japan
关键词
Sesamin; Warfarin; CYP2C9; Human liver microsomes; Competitive inhibition; ANTIOXIDATIVE METABOLITES; EPISESAMIN; LIVER; CYTOCHROME-P450; LIGNAN;
D O I
10.1016/j.dmpk.2020.05.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A recent report demonstrated that sesamin strongly and non-competitively inhibits S-warfarin 7-hydroxylation activity in human liver microsomes with a K-i value of 0.2 mu M. This finding suggests that sesamin predominantly binds to CYP2C9 at another site for which it has a higher affinity than its affinity for the active site, thereby inhibiting the activity of CYP2C9 non-competitively. In this study, we found that sesamin competitively inhibited the 7-hydroxylation activity of S-warfarin in human liver microsomes with a K-i value of 15.7 mu M. In addition, the recombinant CYP2C9-dependent 7-hydroxylation activity of S-warfarin was competitively inhibited by sesamin with a Ki value of 13.1 mu M. These results are consistent with the fact that sesamin is a good substrate of CYP2C9, and its activity follows Michaelis-Menten kinetics. As the plasma concentration of sesamin after its administration is usually lower than 0.01 mu M, the inhibition of S-warfarin metabolism by sesamin does not appear to be severe. (C) 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 42 条
[31]   The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients [J].
Akdeniz, Cansu Selcan ;
Cevik, Mehtap ;
Canbolat, Ismail Polat ;
Yurdakul, Selen ;
Cagatay, Penbe ;
Ciftci, Cavlan ;
Karaalp, Atila ;
Susleyici, Belgin .
FUTURE CARDIOLOGY, 2020, 16 (06) :645-654
[32]   Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy [J].
Al-Eitan, Laith N. ;
Almasri, Ayah Y. ;
Khasawneh, Rame H. .
SAUDI PHARMACEUTICAL JOURNAL, 2019, 27 (04) :484-490
[33]   In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants [J].
Jin, Shasha ;
Paludetto, Marie-Noelle ;
Kurkela, Mika ;
Kahma, Helina ;
Neuvonen, Mikko ;
Xiang, Xiaoqiang ;
Cai, Weimin ;
Backman, Janne T. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 203
[34]   Electrochemical determination of (S)-7-hydroxywarfarin for analysis of CYP2C9 catalytic activity [J].
Kuzikov, Alexey, V ;
Filippova, Tatiana A. ;
Masamrekh, Rami A. ;
Shumyantseva, Victoria V. .
JOURNAL OF ELECTROANALYTICAL CHEMISTRY, 2022, 904
[35]   In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors [J].
Filppula, Anne M. ;
Neuvonen, Pertti J. ;
Backman, Janne T. .
DRUG METABOLISM AND DISPOSITION, 2014, 42 (07) :1202-1209
[36]   Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients [J].
Nassr Eldin M. A. Shrif ;
Hong-Hee Won ;
Seung-Tae Lee ;
Jun-Hee Park ;
Ka-Kyung Kim ;
Min-Ji Kim ;
Seonwoo Kim ;
Soo-Youn Lee ;
Chang-Seok Ki ;
Ihsan M. Osman ;
Enaam A. Rhman ;
Ibtisam A. Ali ;
M. N. A. Idris ;
Jong-Won Kim .
European Journal of Clinical Pharmacology, 2011, 67 :1119-1130
[37]   Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients [J].
Shrif, Nassr Eldin M. A. ;
Won, Hong-Hee ;
Lee, Seung-Tae ;
Park, Jun-Hee ;
Kim, Ka-Kyung ;
Kim, Min-Ji ;
Kim, Seonwoo ;
Lee, Soo-Youn ;
Ki, Chang-Seok ;
Osman, Ihsan M. ;
Rhman, Enaam A. ;
Ali, Ibtisam A. ;
Idris, M. N. A. ;
Kim, Jong-Won .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (11) :1119-1130
[38]   Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin [J].
Lertkiatmongkol, Panida ;
Assawamakin, Anunchai ;
White, George ;
Chopra, Gaurav ;
Rongnoparut, Pornpimol ;
Samudrala, Ram ;
Tongsima, Sissades .
PLOS ONE, 2013, 8 (09)
[39]   S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction [J].
Chang, Andrew T. ;
Bertino, Joseph S. ;
Nafziger, Anne N. ;
Kashuba, Angela D. M. ;
Turpault, Sandrine ;
Lewis, Lionel D. ;
Ma, Joseph D. .
THERAPEUTIC DRUG MONITORING, 2016, 38 (03) :383-387
[40]   Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms [J].
Farzamikia, Negin ;
Sakhinia, Ebrahim ;
Afrasiabirad, Abbas .
LABORATORY MEDICINE, 2018, 49 (01) :25-34